Kamada Ltd. (NASDAQ:KMDA) Sees Large Growth in Short Interest

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 166,435 shares, a growth of 112.9% from the January 29th total of 78,160 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average trading volume of 69,886 shares, the short-interest ratio is presently 2.4 days. Based on an average trading volume of 69,886 shares, the short-interest ratio is presently 2.4 days. Currently, 0.5% of the shares of the stock are short sold.

Institutional Trading of Kamada

A number of institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC raised its holdings in shares of Kamada by 417.1% in the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 3,862 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Kamada in the fourth quarter valued at approximately $66,000. Simplicity Wealth LLC purchased a new stake in Kamada in the third quarter valued at approximately $70,000. XTX Topco Ltd bought a new stake in Kamada during the fourth quarter valued at approximately $103,000. Finally, SIH Partners LLLP purchased a new position in Kamada in the 4th quarter worth approximately $134,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on KMDA shares. HC Wainwright increased their price target on shares of Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a research note on Thursday, January 22nd. Benchmark reiterated a “buy” rating on shares of Kamada in a research report on Thursday, January 8th. Finally, Wall Street Zen raised Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Kamada Stock Down 2.4%

KMDA traded down $0.21 on Friday, hitting $8.70. The company’s stock had a trading volume of 52,124 shares, compared to its average volume of 69,531. Kamada has a 12 month low of $5.54 and a 12 month high of $9.35. The firm has a market cap of $500.34 million, a P/E ratio of 24.17, a price-to-earnings-growth ratio of 0.74 and a beta of 0.94. The company’s 50 day simple moving average is $8.08 and its 200-day simple moving average is $7.34.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.